Denise M. Boudreau, RPh, PhD
Research interests and experience
- Medication use & patient safety: general drug safety research; pharmaco-epidemiology; observational study research methods; active surveillance on the safety of pharmaceuticals; validation of pharmacy data sources; pharmacy practice research
- Health services & economics: pharmaceutical outcomes research; cost-effectiveness analysis; impact of benefit designs on clinical and economic endpoints; burden of illness
- Cancer control: clinical and biologic effect of commonly used medications on cancer risk and outcomes; cost-effectiveness of chemotherapy
Pharmaco-epidemiologist Denise Boudreau plays an integral role in Group Health Research Institute (GHRI) investigations into medication safety and cost-effectiveness of pharmaceuticals. Known at the Institute for her expertise in pharmaco-epidemiologic methods, she has diverse experience spanning pharmacies, classrooms, and research institutions.
Dr. Boudreau worked as a pharmacist and research associate for six years before earning her PhD from the Pharmaceutical Outcomes and Research Policy Program at the University of Washington (UW) in 2002. She began her career at GHRI in 2003 as a research associate and was promoted to investigator just two years later. Dr. Boudreau is an associate affiliate professor in the UW School of Pharmacy and has co-led their pharmaco-epidemiology course since 2008. She also serves on several student thesis and dissertation committees.
Dr. Boudreau is adept at working with automated health plan data and has expertise in observational study design, managed care, drug safety, and economic evaluation. She brings an in-depth working knowledge of Group Health pharmacy data and practices to her research, which ranges from cancer to cardiovascular disease to opioid use. The principal investigator on several studies looking at the link between prescription medications and both cancer risk and outcomes—such as news-making statins—her latest project explores the influence of commonly used medications such as statins and chronic antibiotic use on breast cancer outcomes.
Among her newest areas of interest is opioid use and misuse—including investigating trends and risks of long-term use to manage chronic pain. She has been the HMO Research Network Steering Committee Representative for the Food and Drug Administration Mini Sentinel Initiative for the past four years and is extensively involved in developing both the data and methods for signal detection of adverse events. Dr. Boudreau is also an expert at pharmaco-economic studies—looking, for example, at the costs and effects of using medications on biologic and screening endpoints for breast cancer and the economic burden of risk factors for metabolic syndrome.
Dr. Boudreau’s research has been exhibited internationally at conferences such as the International Society for Pharmacoepidemiology, the International Society for Pharmacoeconomics and Outcomes Research, and the Congress of Epidemiology. Her professional memberships include the International Society for Pharmacoepidemiology and the International Society for Pharmacoeconomics and Outcomes Research. She retains her pharmacy license in Washington and Rhode Island.
- HMO Research Network
- FDA Mini Sentinel
- International Society for Pharmacoepidemiology
- International Society for Pharmacoeconomics and Outcomes Research
Raebel MA, Newcomer SR, Reifler LM, Boudreau D, Elliott TE, DeBar L, Ahmed A, Pawloski PA, Fisher D, Donahoo WT, Bayliss EA. Chronic use of opioid medications before and after bariatric surgery. JAMA. 2013;310(13):1369-76. doi: 10.1001/jama.2013.278344. PubMed
Chubak J, Boudreau DM, Wirtz HS, McKnight B, Weiss NS. Threats to validity of nonrandomized studies of postdiagnosis exposures on cancer recurrence and survival. J Natl Cancer Inst. 2013 Aug 12 [Epub ahead of print]. PubMed
Matlock DD, Groeneveld PW, Sidney S, Shetterly S, Goodrich G, Glenn K, Xu S, Yang L, Farmer SA, Reynolds K, Cassidy-Bushrow AE, Lieu T, Boudreau DM, Greenlee RT, Tom J, Vupputuri S, Adams KF, Smith DH, Gunter MJ, Go AS, Magid DJ. Geographic variation in cardiovascular procedure use among Medicare fee-for-service vs Medicare Advantage beneficiaries. JAMA. 2013;310(2):155-62. doi: 10.1001/jama.2013.7837. PubMed
Wirtz HS, Buist DS, Gralow JR, Barlow WE, Gray SL, Chubak J, Yu O, Bowles EJ, Fujii M, Boudreau DM. Frequent antibiotic use and second breast cancer events. Cancer Epidemiol Biomarkers Prev. 2013 Jul 5 [Epub ahead of print].
Chubak J, Yu O, Buist DS, Wirtz HS, Boudreau DM. Time scale in follow-up studies: considering disease prognosis. Epidemiology. 2013;24(4):628-9. doi: 10.1097/EDE.0b013e3182961708. PubMed
Lo Re V 3rd, Haynes K, Goldberg D, Forde KA, Carbonari DM, Leidl KB, Hennessy S, Reddy KR, Pawloski PA, Daniel GW, Cheetham TC, Iyer A, Coughlin KO, Toh S, Boudreau DM, Selvam N, Cooper WO, Selvan MS, Vanwormer JJ, Avigan MI, Houstoun M, Zornberg GL, Racoosin JA, Shoaibi A. Validity of diagnostic codes to identify cases of severe acute liver injury in the U.S. Food and Drug Administration's Mini-Sentinel Distributed Database. Pharmacoepidemiol Drug Saf. 2013 Aug;22(8):861-72. doi: 10.1002/pds.3470. Epub 2013 Jun 25. PubMed
Zhou Y, Boudreau DM, Freedman AN. Trends in use of aspirin and other nonsteroidal antiinflammatory drugs in the general U.S. population. Pharmacoepidemiol Drug Saf. 2013 May 30. doi: 10.1002/pds.3463. [Epub ahead of print]. PubMed
Kulldorff M, Dashevsky I, Avery TR, Chan AK, Davis RL, Graham D, Platt R, Andrade SE, Boudreau D, Gunter MJ, Herrinton LJ, Pawloski PA, Raebel MA, Roblin D, Brown JS. Drug safety data mining with a tree-based scan statistic. Pharmacoepidemiol Drug Saf. 2013 May;22(5):517-23. doi: 10.1002/pds.3423. Epub 2013 Mar 20. PubMed
Boudreau DM, Wirtz H, Von Korff M, Catz SL, St John J, Stang PE. A survey of adult awareness and use of medicine containing acetaminophen. Pharmacoepidemiol Drug Saf. 2013 Mar;22(3):229-40. doi: 10.1002/pds.3335. Epub 2012 Aug 13. PubMed
Wong WB, Lin VW, Boudreau D, Devine EB. Statins in the prevention of dementia and Alzheimer's disease: a meta-analysis of observational studies and an assessment of confounding. Pharmacoepidemiol Drug Saf. 2013 Apr;22(4):345-58. doi: 10.1002/pds.3381. Epub 2012 Dec 6. PubMed
To view more publications, please see Dr. Boudreau's CV.